OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Subscription and Copyright Information	887
Shearing of surface mucin saps tumor cell strength	564
Subscription and Copyright Information	427
Structural asymmetry in FGF23 signaling	225
Advisory Board and Contents	224
Subscription and Copyright Information	190
Subscription and Copyright Information	165
Muscarinic receptors: from clinic to bench to clinic	158
Subscription and Copyright Information	157
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	151
Swinging the SWI/SNF complexes for cancer therapy	143
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	134
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	128
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	126
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	122
Compstatins: the dawn of clinical C3-targeted complement inhibition	120
Peptides as a therapeutic strategy against Klebsiella pneumoniae	119
Direct in vivo CAR T cell engineering	116
Structural pharmacology and mechanisms of GLP-1R signaling	106
Therapeutic inhibition of ferroptosis in neurodegenerative disease	95
Targeting complement in neurodegeneration: challenges, risks, and strategies	88
Nemolizumab (Nemluvio®) for prurigo nodularis	87
Ribosome-directed cancer therapies: the tip of the iceberg?	86
Advisory Board and Contents	86
Phenotypic approaches for CNS drugs	86

A deep dive into degrader-induced protein-protein interfaces	84
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	80
Advisory Board and Contents	80
A perspective on psychedelic teratogenicity: the utility of zebrafish models	77
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	75
Optogenetic engineering for precision cancer immunotherapy	75
Advisory Board and Contents	75
Engineering ACE2 decoy receptors to combat viral escapability	73
Emerging strategies for beta cell transplantation to treat diabetes	72
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	71
A smart hospital-driven approach to precision pharmacovigilance	69
HSV-1 as a gene delivery platform for cancer gene therapy	69
Genetically engineered loaded extracellular vesicles for drug delivery	66
Leveraging human microbiomes for disease prediction and treatment	66
siRNA drug Leqvio (inclisiran) to lower cholesterol	65
Close to a year in TIPS’ saddle – I am optimistic	62
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	59
Subscription and Copyright Information	59
Thriving as members of under-represented groups in pharmacology-related careers	58
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	57
Advisory Board and Contents	56
Bimetallic nanoadjuvants for cancer vaccines	56
Subscription and Copyright Information	55
Lipoxygenases in chronic liver diseases: current insights and future perspectives	54
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	52
Emerging approaches to induce immune tolerance to therapeutic proteins	50
Mentoring future science leaders to thrive	49
Suzetrigine for moderate to severe acute pain	49
Could dexmedetomidine be repurposed as a glymphatic enhancer?	48
Advancing non-destructive analysis of 3D printed medicines	47
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	46
Autologous, allogeneic, in vivo CAR for autoimmune diseases	45
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	45
The structure, function, and pharmacology of MRGPRs	45
Now you serine, now you don't	43
Piezo1: structural pharmacology and mechanotransduction mechanisms	42
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	42
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	42
Advisory Board and Contents	41
The promise of targeted protein degradation approaches	41
The road less traveled: activating an oncogenic kinase	41
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	40
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	40
Salt-inducible kinases: new players in pulmonary arterial hypertension?	39
A novel function of the M2 muscarinic receptor	38
Promising neuroimmune targets and drugs for CNS diseases	37
Subscription and Copyright Information	37
Validation of agent-based models of surface receptor oligomerisation	37
The end of the beginning in understanding SLC22 polyspecificity	37
Advisory Board and Contents	37

Frizzleds act as dynamic pharmacological entities	36
Beyond G protein and arrestin: GRK2-biased β₂AR signaling	36
Tackling microbial iron homeostasis: novel antimicrobial strategies	35
Targeting intracellular protein–protein interactions with macrocyclic peptides	34
Monkeypox: potential vaccine development strategies	34
Decoding pseudouridine: an emerging target for therapeutic development	34
Protein acylations in cancer immunity: effects and therapeutic opportunities	34
Advisory Board and Contents	33
Artificial intelligence in rare diseases: toward clinical impact	33
BTK inhibitors: past, present, and future	33
Metabolic regulation in normal and leukemic stem cells	32
Subscription and Copyright Information	32
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	31
Recent advances in generative biology for biotherapeutic discovery	31
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	30
GPR35: from enigma to therapeutic target	30
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	30
Development of PROTACs using computational approaches	30
Engineered antibody fusion proteins for targeted disease therapy	29
Circulating tumor cells in precision medicine: challenges and opportunities	29
Eflornithine for treatment of high-risk neuroblastoma	29
Demographic diversity in platelet function and response to antiplatelet therapy	29
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	28
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	28
Targeting plasma membrane cholesterol as a novel anticancer therapy	28
Subscription and Copyright Information	27
Subscription and Copyright Information	27
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	26
Tackling chronic kidney disease in diabetic patients with finerenone	26
Subscription and Copyright Information	26
Harnessing associative learning paradigms to optimize drug treatment	26
Visceral obesity and HFpEF: targets and therapeutic opportunities	25
Biologics and cardiac disease: challenges and opportunities	25
Boosting CAR-T cell therapy through vaccine synergy	25
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	25
High-power screening (HPS) empowered by DNA-encoded libraries	25
A novel anticancer pharmacological agent targeting mitochondrial complex I	24
The structure, function, and pharmacology of SK channel family	24
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	24
Recent advancements in vaccine research and development	23
Targeting sensory neuron GPCRs for peripheral neuropathic pain	23
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	23
Neutrophil extracellular traps in wound healing	23
Circadian biology to advance therapeutics for mood disorders	22
WEE-family kinases in cancer: synthetic lethal interactions and drug discovery	22
Subscription and Copyright Information	22
Challenges and opportunities associated with rare-variant pharmacogenomics	22
Multitargeting neuroimmune pathways: novel candidates for chronic pain relief	22
GABAA receptors as targets for treating affective and cognitive symptoms of depression	21
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	21
The ABCs of psychedelics: a preclinical roadmap for drug discovery	21
Taming PRMT5–adaptor protein interactions	21
NLRP3 and pyroptosis blockers for treating inflammatory diseases	20
Subscription and Copyright Information	20
Advisory Board and Contents	20
Potential for targeting small heat shock protein modifications	19
The structure and function of YTHDF epitranscriptomic m6A readers	19
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	19
Targeted protein degrader development for cancer: advances, challenges, and opportunities	18
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	18
Malolactone strikes: K-Ras-G12D's Achilles' heel	18
Odorant receptors as potential drug targets	18
Glymphatic-stagnated edema induced by traumatic brain injury	18
Subscription and Copyright Information	18
GPCR-dependent and -independent arrestin signaling	18
Advisory Board and Contents	18
Hans Jürg Schatzmann (1924–2021)	18